[144] The Cigna Group SEC Filing

Rhea-AI Filing Summary

Form 144 filing for Cigna (CI) reports a proposed sale of 28,526 common shares through Fidelity Brokerage Services on the NYSE, with an aggregate market value of $8,557,800 and approximately 266,928,075 shares outstanding. The shares to be sold were acquired via restricted stock vesting (1,137 shares on 03/01/2024) and option exercises or option-related transactions (2,636 shares on 08/13/2024; 13,155 shares and 11,598 shares with dates shown as 08/15/2025 tied to options granted in 2018 and 2019). No securities were reported sold in the past three months. The filer attests they are not aware of any material nonpublic information.

Positive

• Complete disclosure of broker, share count, aggregate market value, and acquisition history demonstrating compliance with Rule 144
• No sales in the past three months are reported, reducing immediate concerns about a pattern of recent insider disposals
• Attestation that the filer does not possess undisclosed material adverse information

Negative

• Insider proposed sale of 28,526 shares with an aggregate market value of $8,557,800, representing meaningful insider liquidity

Insights

Securities Analyst

TL;DR: Insider plans to sell $8.56M of CI stock; filings appear routine and disclose recent option and restricted stock activity.

The notice details a proposed sale of 28,526 common shares with an aggregate market value of $8,557,800 and lists the acquisition sources: restricted stock vesting and option exercises/grants. The filing is procedural under Rule 144 and includes the required attestation about material nonpublic information. There are no reported sales in the prior three months, which suggests this transaction is not part of an ongoing high-frequency disposal pattern disclosed here. For investors, the filing documents insider liquidity but provides no operational or financial performance information.

Corporate Governance Expert

TL;DR: Filing demonstrates compliance with disclosure rules; the attestation reduces governance-related uncertainty.

The Form 144 supplies the broker, sale timing, share counts, and acquisition history as required, including that the filer represents no undisclosed material adverse information. That representation, together with a clear breakdown of acquisition types (restricted stock vesting and option exercises), reflects adherence to disclosure protocols. The filing does not indicate any unusual arrangements or withheld information, and no prior three-month sales are reported, which is relevant for assessing insider disposal patterns.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	28526	8557800.00	266928075	08/15/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/01/2024	Restricted Stock Vesting	Issuer			1137	03/01/2024	Compensation
Common	08/13/2024	Stock Option Exercise	Issuer			2636	08/13/2024	Cash
Common	08/15/2025	Option Granted - 02/28/2018	Issuer			13155	08/15/2025	Cash
Common	08/15/2025	Option Granted - 02/27/2019	Issuer			11598	08/15/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed for Cigna (CI) report?

The form reports a proposed sale of 28,526 common shares through Fidelity on the NYSE with an aggregate market value of $8,557,800.

When is the approximate date of the proposed sale?

The filing lists the approximate sale date as 08/15/2025.

How were the shares being sold acquired?

Acquisitions listed include restricted stock vesting on 03/01/2024 (1,137 shares), a stock option exercise on 08/13/2024 (2,636 shares), and option-related entries dated 08/15/2025 for 13,155 and 11,598 shares tied to options granted in 2018 and 2019.

Did the filer sell any securities of the issuer in the past three months?

No. The filing states Nothing to Report for securities sold during the past three months.

Which broker is handling the proposed sale?

The sale is to be handled by Fidelity Brokerage Services LLC, 900 Salem Street, Smithfield RI.

Does the filer assert possession of any undisclosed material information?

No. The filer represents by signing the notice that they do not know any material adverse information about the issuer that has not been publicly disclosed.